Acknowledgements
Cancer, A. Jayakkumaran, Breast Cancer, tumor
ONCOLOGY, TUMOR, BREAST CANCER, CANCER
We are grateful to the participants and their families for participating in the trial. We thank all supporting clinical trial staff, in particular M. Jansen, G. de Vries and the Departments of Medical Oncology, Radiology, Pathology and Dermatology of the participating centers. We thank the triallab of the NKI for handling incoming blood samples. We acknowledge the Scientific Administration departments of participating centers, particularly A. Jayakkumaran and M. Sondermeijer. We thank M. Holtkamp and K. Kersten for participant visits and supporting the scheduling of participants. We are grateful to the Core Facility of Molecular Pathology and Biobanking for the storage and handling of human tumor material and to the Genomics Core Facility, in particular R. Kluin, W. Brugman and C. van Steenis, for DNA and RNA sequencing. We thank M. Bruggeman, M. Duijst and C. Klaver for blood sample experiments and the Flow Cytometry Facility for support in these experiments. We acknowledge PALGA, the Dutch Pathology Registry, for enabling collection of archived material. We thank R. Meijer and J. Paardekooper Overman from Roche for enabling the trial and arranging supply of atezolizumab. R.S. is supported by the Breast Cancer Research Foundation (grant number 17-194). Research at the NKI is supported by institutional grants of the Dutch Cancer Society and of the Dutch Ministry of Health, Welfare and Sport. Research in the laboratory of M.K. is funded by the Netherlands Organization for Scientific Research (NWO-VIDI 09150172010043) and the Hendrika Roet fund. This work was supported by F. Hoffmann-La Roche, Ltd., Basel, Switzerland (no grant numbers apply). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.